Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through Training and Preclinical Support (U54 Clinical Trial Not Allowed)
No gotchas detected. Always read the full FOA/NOFO.
Synopsis
The National Institute on Drug Abuse (NIDA) seeks to advance its mission by establishing a Center that educates and supports researchers in formal product development for new substance use disorder (SUD) pharmacotherapeutics. The Center will also help advance the best concepts through initial experiments via technical and financial support. Previous NIDA-supported initiatives in early translational research have shown that drug addiction researchers are eager to acquire formal product development skills and access technical expertise and support. Prospective applicants are encouraged to: develop plans for a product development curriculum to be taught to SUD researchers, outline outreach and networking initiatives to engage the research community and recruit researchers' concepts for development within the Center, and describe the infrastructure support that may be provided for initial experiments.
Applications are not being solicited at this time. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive applications. Investigators with expertise in the areas of drug discovery and development and institutional capacities to support such a Center are encouraged to begin to consider applying for this NOFO.Grant authorities that allow NIH to forecast this opportunity are as follows Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75 and 2 CFR Part 200].